CRI Funded Scientists

Vincenzo Bronte, MD, CLIP Investigator

Universita di Verona (Italy)

Area of Research: All Cancers, Cáncer de mama, Pancreatic Cancer

The clinical efficacy of checkpoint immunotherapy is still limited to a minority of patients, likely because cancers enforce multifaceted resistance mechanisms. In this context, pancreatic cancer represents a devastating disease in which immunotherapy does not work. The immune suppressive pancreatic cancer microenvironment, mainly enforced by myeloid and fibrotic cell infiltration, can turn off the adaptive arms of the immune response, including killer T cells.

Dr. Bronte’s studies shed light on a new class of proteins involved in T cell homing and retention within the tumor core. By comparing “cold” and “hot” pancreatic cancers, he unveiled a role of a tight junction protein as a forerunner of unique cancer suppressors that shape the anti-tumor immune response. Now, the aim of Bronte’s work is to identify the protein binding partner(s) on T cells, characterize the functional consequences of this interaction on both tumor and immune cells, and explore approaches to heat “cold” tumors and thus offer novel immunotherapy solutions for patients with pancreatic cancer.

Projects and Grants

CHARON: Claudins Help the Arrest of Cytotoxic T Lymphocytes in Tumors Improving Immunotherapy

Universita di Verona (Italy) | Pancreatic Cancer | 2020

Neutralizing human arginase to enhance cancer immunotherapy

Universita di Verona (Italy) | All Cancers, Breast Cancer, Pancreatic Cancer | 2017


Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer

Francesco De Sanctis et al | Journal for ImmunoTherapy of Cancer | 2022 | DOI

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.